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Objectives The purpose of this study was to evaluate the feasibility and safety of periprocedural dabigatran during atrial
fibrillation (AF) ablation.
Background AF ablation requires optimal periprocedural anticoagulation for minimizing bleeding and thromboembolic com-
plications. The safety and efficacy of dabigatran as a periprocedural anticoagulant for AF ablation are unknown.
Methods We performed amulticenter, observational study from a prospective registry including all consecutive patients undergoing
AF ablation in 8 high-volume centers in the United States. All patients receiving dabigatran therapy who underwent AF abla-
tion on periprocedural dabigatran, with the dose held on the morning of the procedure, were matched by age, sex, and type
of AF with an equal number of patients undergoing AF ablation with uninterrupted warfarin therapy over the same period.
Results A total of 290 patients, including 145 taking periprocedural dabigatran and an equal number of matched pa-
tients taking uninterrupted periprocedural warfarin, were included in the study. The mean age was 60 years with
79% being male and 57% having paroxysmal AF. Both groups had a similar CHADS2 score, left atrial size, and
left ventricular ejection fraction. Three thromboembolic complications (2.1%) occurred in the dabigatran group
compared with none in the warfarin group (p  0.25). The dabigatran group had a significantly higher major
bleeding rate (6% vs. 1%; p  0.019), total bleeding rate (14% vs. 6%; p  0.031), and composite of bleeding
and thromboembolic complications (16% vs. 6%; p  0.009) compared with the warfarin group. Dabigatran use
was confirmed as an independent predictor of bleeding or thromboembolic complications (odds ratio: 2.76, 95%
confidence interval: 1.22 to 6.25; p  0.01) on multivariate regression analysis.
Conclusions In patients undergoing AF ablation, periprocedural dabigatran use significantly increases the risk of bleeding or
thromboembolic complications compared with uninterrupted warfarin therapy. (J Am Coll Cardiol 2012;59:
1168–74) © 2012 by the American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.12.014Atrial fibrillation (AF) is the most common sustained
cardiac arrhythmia and is associated with significantly in-
creased morbidity and mortality (1,2). Radiofrequency cath-
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challenging and is associated with a small but definite risk of
periprocedural thromboembolic and bleeding complications
(4–6). The increased risk of thromboembolic complications
is likely related to the exacerbation of the baseline pro-
thrombotic state by catheters in the left atrium (LA),
endothelial denudation, char formation, and tissue inflam-
mation from ablation in the LA (4,5,7). The thromboem-
bolic risk can be minimized by adequate periprocedural
anticoagulation, which could potentially increase the risk of
bleeding complications (8).
See page 1175
Optimal periprocedural anticoagulation protocols to min-
imize these complications are still largely debated and are
nonuniform (4,5). AF ablation on therapeutic anticoagula-
tion with warfarin, with an international normalized ratio
between 2 and 3, has been shown to be safe and is becoming
increasingly adopted by several institutions (9–13). Recently,
dabigatran, an oral direct thrombin inhibitor, was approved for
the prevention of stroke in patients with nonvalvular AF
(3,14). Management of periprocedural anticoagulation in pa-
tients on dabigatran undergoing AF ablation is not known. We
aimed to evaluate the feasibility and safety of continuing
dabigatran during the periprocedural period of AF ablation in
a multicenter, observational study.
Methods
We performed a multicenter, observational study from a
prospectively collected registry of patients undergoing AF
ablation for drug-refractory, symptomatic AF at 8 high-
volume electrophysiology laboratories between January 2010
and July 2011. The study protocol was approved by local
institutional review board. The dabigatran group consisted
of all consecutive patients receiving anticoagulation therapy
with 150 mg dabigatran etexilate (Pradaxa) twice daily for at
least 30 days before the AF ablation procedure. An equal
number of patients who were matched for age, sex, and type
of AF undergoing AF ablation at respective institutions
during the same period receiving therapeutic anticoagula-
tion with warfarin for at least 30 days before the procedure
comprised the warfarin group. Patients were excluded if the
international normalized ratio was not between 2.0 and 3.5
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gation system.
Periprocedural anticoagulation.
Patients taking dabigatran were
instructed to hold the dose on
the morning of the procedure.
Dabigatran was resumed within
3 h after hemostasis and when
the patient was ready to have oral
intake after the ablation proce-
dure. Patients in the warfarin
group underwent catheter abla-
tion on uninterrupted warfarin therapy throughout the
periprocedural period, including the evening of the
procedure.
Ablation procedure. Transesophageal echocardiography
was performed on all dabigatran patients to rule out a left
atrial appendage thrombus, whereas it was not performed
on patients in the warfarin group. During the ablation
procedure, a bolus of 10,000 U of unfractionated heparin
(UH) was given before the transseptal puncture. The
activated clotting time (ACT) was checked 15 min after the
bolus and every 20 min thereafter. Further weight-adjusted
UH boluses were given to maintain an ACT of 300 to 400 s
while catheters remained in the LA. Pulmonary vein antral
isolation (PVAI) using a double transseptal approach was
described in detail elsewhere (15). Briefly, under intracar-
diac echocardiography guidance, 2 transseptal accesses were
obtained using standard needles and sheaths. The location,
number, and size of venous sheaths and recording catheters
were at the operator’s discretion. A circular mapping cath-
eter (Lasso, Biosense Webster Inc., Diamond Bar, Califor-
nia or Spiral, St. Jude Medical, Minneapolis, Minnesota)
was used to map the LA. A 3-dimensional geometry of the
LA was reconstructed with the CARTO (Biosense Webster
Inc.) or the NavX mapping system (St. Jude Medical). A
3.5-mm open irrigated tip catheter (ThermoCool, Biosense
Webster Inc.) was used to ablate the antrum of the
pulmonary veins to achieve electrical isolation. Radiofre-
quency energy output was titrated to a maximum of 40 to 45
W along the anterior segments and 30 to 35 W while
ablating the posterior segments. The exact number and
extent of lesions were according to the operator’s preference
and were tailored to the individual patient.
In cases of paroxysmal AF, only PVAI was performed.
The procedural endpoint of this ablation strategy was
achieving entry and exit blocks. In patients with persistent
AF, additional substrate modification involving complex
fractionated atrial electrograms, identified by either the
mapping catheter or the 3-dimensional map was also
performed. Complex fractionated atrial electrograms along
the posterior wall, left atrial septum, left atrial roof, coronary
sinus, left atrial appendage base, and crista terminalis were
Abbreviations
and Acronyms
ACT  activated clotting
time
AF  atrial fibrillation
CI  confidence interval
LA  left atrium
OR  odds ratio
PVAI  pulmonary vein
antral isolation
UH  unfractionated
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lines and mitral isthmus lines to ablate residual left atrial
tachycardia after PVAI and complex fractionated atrial
electrogram ablation together with coronary sinus and left
atrial appendage isolation was also performed in some
patients according to the operator’s preference. Further
ablation at the superior vena cava and right atrial junction
was also performed at operator’s discretion if mapping
revealed double potentials around this region and when
high-output (30 mA) pacing did not capture the phrenic
nerve. In addition, 20 g/min isoproterenol was adminis-
tered for 15 min to disclose non-pulmonary vein triggers
that were ablated. Finally, if AF did not terminate after
PVAI and substrate modification, direct current cardiover-
sion was performed to achieve normal sinus rhythm.
Data collection. Demographic, procedural, and complica-
tion data were obtained from prospectively collected regis-
tries in each of the participating centers. Events occurring
within the first 30 days after the ablation procedure were
included in this current analysis.
Safety endpoints. Hematomas and pericardial effusions were
considered as bleeding complications. Cerebrovascular acci-
dents and transient ischemic attacks were considered throm-
boembolic complications after ruling out intracranial hemor-
rhage. Any bleeding requiring blood transfusion, hematomas
requiring surgical intervention, and pericardial effusions requir-
ing drainage (tamponade) were considered as major bleeding
complications. Minor bleeding complications included small
hematomas and pericardial effusions not requiring an interven-
tion (nontamponade). Late pericardial tamponades were those
occurring 48 h after the procedure. The primary safety
outcome measured was a composite of bleeding and thromboem-
bolic complications. Miscellaneous nonanticoagulation-related
events were also recorded.
Reversal of anticoagulation. In the event of a bleeding
complication that required reversal of anticoagulation, fresh
frozen plasma with possible hemodialysis was considered in the
dabigatran group. In the warfarin group, vitamin K was
considered in addition to fresh frozen plasma at operator’s
discretion.
Statistical analysis. Patients in both groups were matched by
age (2 years), sex, type of AF, and the institution where the
procedure was performed. Tests for independent samples were
selected throughout because other unmatched variables could
remain that influence treatment efficacy. Both groups were
compared using the chi-square test or Fisher exact test where
appropriate for categorical variables and the independent Stu-
dent t test for continuous variables. Bleeding complications
major, minor, and total), thromboembolic complications, and
omposite of bleeding and thromboembolic complications
ere compared between both groups.
A multivariable logistic model was used for identifying
ignificant predictors of complications. All potential con-
ounders were entered into the model based on clinical
ignificance or observed univariable association. The con-
rolling variables forced in the model were age (dichoto-ized at 75 years), sex, and AF type. The odds ratio (OR)
nd 95% confidence interval (CI) of composite bleeding and
hromboembolic complications were computed. A p value
0.05 (2-sided) was considered statistically significant. All
nalyses were performed with SPSS version 19.0 for Win-
ows (SPSS, Inc., Chicago, Illinois).
esults
aseline and procedural characteristics. The patient pop-
lation comprised 290 patients with 145 patients in each
Comparison of Baseline Demographics,linic l Parameters, and Medication UseBetween Patients on Dabigatran nd Warfarin
Table 1
Compariso of Baseline Demographics,
Clinical Parameters, and Medication Use
Between Patients on Dabigatran and Warfarin
Baseline Characteristics
Dabigatran
(Cases)
(n  145)
Warfarin
(Controls)
(n  145) p Value
Demographics
Age, yrs 60.4 9.6 60.3 9.6 0.97
Age 75 yrs 10 (7) 6 (4) 0.30
Sex 1.00
Male 114 (79) 114 (79)
Female 31 (21) 31 (21)
Race 0.53
Caucasian 131 (90) 134 (92)
Non-Caucasian 14 (10) 11 (8)
Medical history
AF type
Paroxysmal 83 (57) 83 (57) 1.00
Nonparoxysmal 62 (43) 62 (43)
Redo procedure 26 (18) 33 (23) 0.31
Duration of AF, months (mean) 30 32 28 29 0.98
Heart failure 14 (10) 9 (6) 0.27
Hypertension 76 (52) 72 (50) 0.64
Diabetes 22 (15) 19 (13) 0.61
TIA or stroke 5 (3) 9 (6) 0.27
Coronary artery disease 24 (17) 22 (15) 0.74
Sleep apnea 33 (23) 26 (18) 0.31
COPD 3 (2) 3 (2) 1.00
Chronic renal insufficiency 1 (1) 2 (2) 0.59
CHADS2 score
0 50 (35) 58 (40) 0.54
1 62 (43) 60 (41)
2 33 (23) 27 (19)
CHA2DS2-VASc score 1.6 1.4 1.5 1.3 0.40
HAS-BLED score 1.2 0.9 1.1 0.9 0.37
Mean left atrial size, cm 4.5 2.5 4.4 0.8 0.44
Mean LVEF, % 56 10 56 10 0.89
Medication use
Aspirin 45 (31) 42 (29) 0.70
Clopidogrel 4 (3) 7 (5) 0.36
ACE inhibitor/ARB 53 (37) 38 (26) 0.06
Beta-blocker 90 (62) 67 (46) 0.007
Calcium-channel blocker 35 (24) 49 (34) 0.07
Digoxin 26 (18) 15 (10) 0.06
Statins 68 (47) 49 (34) 0.02
Values are mean  SD or n (%).
ACE  angiotensin-converting enzyme; AF  atrial fibrillation; ARB  angiotensin receptorblocker; COPD  chronic obstructive pulmonary disease; LVEF  left ventricular ejection fraction;
TIA  transient ischemic attack.
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farin groups are shown in Table 1. The mean age of the
study population was 60 years with 79% being male and
57% having paroxysmal AF. There were no differences in
the individual components of the CHADS2 score, mean
HA2DS2-VASc score, HAS-BLED score, left atrial size,
left ventricular ejection fraction, and the presenting rhythm
on arrival at the electrophysiology laboratory between both
groups. In addition, there were no differences in the
procedure time (208 min vs. 203 min; p  0.78), radiofre-
uency ablation time (52 min vs. 55 min; p  0.49),
uoroscopy time (58 min vs. 53 min; p  0.19) between
oth groups (Table 2). Acute procedural success and suc-
essful PVAI did not differ between both groups.
omplications. The comparison of complications between
oth groups is shown in Table 3. A total of 32 patients
11%) had either bleeding and/or embolic complications, of
hom 29 (10%) had bleeding complications and 3 (1%) had
hromboembolic complications. No intracranial hemor-
hage or deaths occurred in the study population Of note, all
thromboembolic complications occurred in nonparoxys-
al patients in the dabigatran group, whereas no thrombo-
mbolic complications occurred in the warfarin group (p 
.25 for comparison). Neurologic symptoms improved in all
patients with no residual deficits noted at 30-day follow-
p. Compared with patients taking warfarin, patients taking
Comparison of Procedural VariablesBetween Patients on Dabigatr n and WarfarinTable 2 Comparison of P ocedural VariablesBetween Patients on Dabigatran and Warfarin
Procedural Variables
Dabigatran
(n  145)
Warfarin
(n  145) p Value
Presenting rhythm
Sinus rhythm 80 (55) 87 (60) 0.40
AF/AFL 65 (45) 58 (40)
Acute success 138 (95) 137 (95) 0.79
Procedural time, min 208 73 203 61 0.78
Fluoroscopy time, min 58 20 53 23 0.19
RF time, min 52 16 55 27 0.49
Intraprocedural cardioversion 36 (25) 30 (21) 0.40
PV isolation 145 (100) 145 (100) 1.0
Values are n (%) or mean  SD.
AF  atrial fibrillation; AFL  atrial flutter; PV  pulmonary vein; RF  radiofrequency.
Comparison of Complications Between Patients on Dabigatran andTable 3 Comparison of Complications Between Patients on Da
Safety Endpoints Dabigatran (n  14
Major bleeding complications 9 (6)
Periprocedural pericardial tamponade 6 (4)
Late pericardial tamponade 3 (2)
Minor bleeding complications 12 (8)
Groin hematoma 6 (4)
Pericardial effusion without tamponade 6 (4)
Total bleeding complications 20 (14)
Embolic complications (CVA/TIA) 3 (2)
Composite of bleeding and embolic complications 23 (16)Values are n (%).
CVA  cerebrovascular accident; TIA  transient ischemic attack.abigatran had a significantly higher major bleeding rate
6% vs. 1%; p  0.019), total bleeding rate (14% vs. 6%;
 0.031), and composite of bleeding and thromboembolic
omplications (16% vs. 6%; p  0.009). All major bleedings
ere pericardial effusions with tamponade requiring drain-
ge (9 patients in the dabigatran group and 1 patient in the
arfarin group), and none of the patients with a groin
ematoma needed an intervention. One patient in the
abigatran group had both a pericardial effusion with
amponade and a groin hematoma. One patient in the
arfarin group had both a pericardial effusion without
amponade and a groin hematoma. None of the patients
eeded hemodialysis for elimination of dabigatran from the
ystemic circulation.
We also analyzed the predictors of complications. The
se of dabigatran in patients with bleeding and/or throm-
oembolic complications was much higher than in patients
ithout these complications (Table 4). In univariable anal-
sis, the only predictors of bleeding were the use of
abigatran (69% vs. 48%; p  0.031) and age older than 75
ears (17% vs. 4%; p  0.004). Dabigatran use (72% vs.
7%; p  0.009) and age older than 75 years (16% vs. 4%;
 0.008) were also the only univariable predictors of the
omposite of bleeding and thromboembolic complications.
n multivariable logistic regression analysis including age
lder than 75, sex, AF type, and the use of dabigatran, the
nly independent predictors of bleeding or thromboembolic
omplications were dabigatran use (OR: 2.76, 95% CI: 1.22
o 6.25; p  0.01) and age older than 75 (OR: 3.82, 95%
CI: 1.09 to 13.35; p  0.04). Dabigatran use was found to
be an independent predictor of both bleeding complications
(OR: 2.34, 95% CI: 1.02 to 5.39; p 0.046) and composite
of bleeding and thromboembolic complications.
Discussion
In our multicenter, observational study, we found that the
use of dabigatran periprocedurally for AF ablation was
associated with an increased risk of bleeding and composite
of bleeding and thromboembolic complications compared
with uninterrupted warfarin anticoagulation.
arinran and Warfarin
Warfarin (n  145) Total (N  290) p Value
1 (1) 10 (3) 0.019
1 (1) 7 (2) 0.12
0 (0) 3 (1) 0.25
8 (6) 20 (7) 0.35
5 (3) 11 (4) 0.76
4 (3) 10 (3) 0.75
9 (6) 29 (10) 0.031
0 (0) 3 (1) 0.25
9 (6) 32 (11) 0.009Warfbigat
5)
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shown to be better than warfarin in preventing stroke in AF
patients with an equivalent bleeding risk and has recently
been approved for use in the United States for nonvalvular
AF (3,14). Although a large number of patients are either
switched from warfarin or started de novo on dabigatran for
systemic anticoagulation, managing its use periprocedurally for
catheter ablation is currently unclear. Our study is the first such
study to systematically evaluate the feasibility and safety of
continuing dabigatran periprocedurally for AF ablation com-
pared with the more accepted warfarin anticoagulation.
Complications after AF ablation. The risk of thrombo-
embolism during and after an AF ablation procedure re-
mains a significant concern due to the inherent nature of the
procedural components (16–19). Some of the common
underlying causes of periprocedural thromboembolism dur-
ing AF ablation are thrombus formation on the catheters
and guide sheaths, endothelial denudation, local tissue
inflammation, dislodgment of an unrecognized left atrial
thrombus, char formation on the catheter tip, and de novo
clot formation due to atrial stunning after restoration of
sinus rhythm with inadequate anticoagulation (5,7,17).
These findings have led to the adoption of several safety
practices such as using an open irrigated ablation catheter,
transesophageal echocardiography to screen for left atrial
thrombus before ablation, maintaining adequate periproce-
dural anticoagulation to prevent thrombus formation on the
atrial surface, and pulling the sheaths back into the right
atrium during ablation. As a result of these aggressive
strategies, the risk of systemic thromboembolism decreased
significantly from 5% to 6% to 1% in the more recent
literature (9,20,21). It is a routine practice to anticoagulate
patients both with UH during the procedure and alternate
anticoagulants for at least 4 weeks after the procedure
Univariate and Multivariate Predictors of Complications (CompositeTable 4 Univariate and Multivariate Predictors of Complication
Univariate Analysis
No Complications
(n  258)
Complications
(n  32)
Age, yrs 60 9 62 12
Female 53 (21) 9 (28)
Age 75 yrs 11 (4) 5 (16)
Body mass index, kg/m2 29.5 6 29.6 5
CHADS2 mean score 0.88 0.90 1.0 1.1
CHADS2 score
0 97 (38) 11 (34)
1 111 (43) 11 (34)
2 50 (19) 10 (31)
Nonparoxysmal AF 110 (43) 14 (44)
Redo procedure 53 (20) 6 (21)
LVEF, % 56 10 57 7
Dabigatran 122 (47) 23 (72)
Aspirin 75 (29) 12 (36)
Values are mean  SD or n (%).
CI  confidence interval; other abbreviations as in Table 1.(21–23). Aggressive anticoagulation in the background ofmultiple venous accesses with moderate to large sheaths,
transseptal accesses, and extensive ablation increases the risk
of bleeding complications (8,16).
Periprocedural anticoagulation. Currently, the periproce-
dural anticoagulation protocols for AF ablation are primar-
ily driven by operator comfort and experience. Several
different anticoagulation protocols consisting of varied com-
binations of antiplatelet agents, warfarin, UH, and low
molecular weight heparin combined with transesophageal
echocardiography screening stratified by baseline risk of
systemic thromboembolism and type of AF have been put to
work (1,4,5). Although there are no established guidelines
supporting the superiority of one periprocedural anticoagu-
lation protocol over the other, it has become increasingly
evident that performing AF ablation with uninterrupted
anticoagulation with warfarin is safe and not associated with
increased bleeding complications compared with other an-
ticoagulants (9–13,24). The recent consensus document
from the European Heart Rhythm Association does men-
tion that uninterrupted warfarin anticoagulation is a poten-
tial alternative to bridging with UH or low molecular weight
heparin (25). Moreover, using an open irrigated ablation
catheter on a background of therapeutic anticoagulation with
warfarin has been shown to be associated with a dramatic
reduction in the risk of thromboembolic events (9).
Dabigatran has a rapid onset of action (0.5 to 2 h), but
the elimination half-life ranges from 12 to 14 h when used
for long-term therapy with a normal creatinine clearance
(26). However, in our study, dabigatran was discontinued
on the morning of the procedure, and almost all procedures
were performed within 1.5 times of the elimination half-life,
when there was a significant residual pharmacodynamic
effect. The safety of overlapping UH and dabigatran has not
been established, in contrast to that of overlapping UH and
leeding and Thromboembolic Complications)mposite of Bleeding and Thromboembolic Complications)
Multivariate Analysis
p Value Odds Ratio 95% CI p Value
0.28
0.18 — — 0.70
0.008 3.82 1.09–13.35 0.04
0.90
0.23
0.28
0.90 — — 0.68
0.96
0.64
0.009 2.76 1.22–6.25 0.01
0.32of Bs (Cowarfarin. Dabigatran is generally recommended to be dis-
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with a standard risk of bleeding and normal renal function
(27). The overlapping pharmacodynamic effects of UH and
dabigatran during the procedure probably explain the in-
creased risk of bleeding in the dabigatran group of our study
population. Our study finding is consistent with that of
previous studies that elderly patients have a higher risk of
complications including bleeding complications during AF
ablation (6,28).
When sorted by AF type, all the thromboembolic com-
plications were seen in nonparoxysmal AF patients. The
incidence of thromboembolic complications in nonparoxys-
mal AF patients in the dabigatran group, although not
statistically different from that of the warfarin group, was
very high (5%) and probably has important clinical rele-
vance. This may be due to the greater extent of ablation in
persistent AF, although our study was not powered to
identify the correlation. The role of atrial substrate or type
of AF in periprocedural thromboembolic events in patients
taking dabigatran needs to be explored further.
It is well recognized that recent (3 to 4 weeks) initiation
of anticoagulation is associated with an increased risk of
bleeding in AF patients and this might have potentially
confounded a part of our results (29). However, the impact
of recent anticoagulation initiation on periprocedural bleed-
ing is not clear. Moreover, all patients in our study were
receiving therapeutic anticoagulation for at least 30 days.
This likely minimized the impact, if any, of recent antico-
agulation initiation on our study results.
Very recently, Winkle et al. (30) described their experi-
ence of using dabigatran post-procedurally after AF ablation
in 123 patients. Less than 30% of them were taking
pre-procedural dabigatran, and it was stopped 36 to 60 h
before the procedure based on patients’ glomerular filtration
rate. Approximately 50% of the patients were taking war-
farin pre-procedurally, which was stopped 5 days prior to
the procedure, and a subcutaneous low molecular weight
heparin bridge was used in them until the procedure. The
intraprocedural ACT was targeted at 225 s. All patients
were started on low molecular weight heparin immediately
after the procedure, and dabigatran was started/restarted
22 h after the procedure. None of the patients experienced
bleeding or thromboembolic complications until 30 days
after the procedure. Their study is significantly different
from our current study in that we evaluated the safety of
periprocedural dabigatran compared with warfarin. Com-
pared with our protocol, Winkle et al. stopped dabigatran
earlier pre-procedurally and restarted it later post-
procedurally. Also, they targeted a much lower ACT (225 s)
compared with our study (300 to 400 s). These differences
in the anticoagulation protocols probably explain the differ-
ences in the bleeding complications between both the
studies.
Although our study provides initial data on slightly
increased bleeding with dabigatran compared with warfarin
in patients undergoing AF ablation, large randomized,controlled studies are required to confirm our results and
identify an optimal periprocedural anticoagulation protocol.
It is possible that holding dabigatran for 24 h without
delaying the first dose after the procedure may decrease
these bleeding complications and needs to be evaluated in
future studies. The lack of any recommended acute reversal
agents for dabigatran, at present, makes the risk of excessive
major bleeding complications all the more important (27).
Study limitations. This was a relatively small observational
study with a matched-control design. Even though, we
conducted a multivariate analysis after adjusting for known
predictors of bleeding complications, it is possible that other
confounding variables affecting the results were unac-
counted for in the study. Another limitation of the study is
that the procedural techniques were operator dependent,
which could potentially confound the results, even though
all our centers predominantly practice a similar protocol.
Nevertheless, a scarcity of data on the safety of continuing
dabigatran during AF ablation procedure makes our study
very important to the current electrophysiology practice,
especially with the increasing use of dabigatran in clinical
practice.
Conclusions
In patients undergoing AF ablation, continuation of dab-
igatran during the periprocedural period is associated with
an increased risk of bleeding and composite of bleeding or
embolic complications compared with uninterrupted warfa-
rin therapy. Further studies are needed to identify the
optimal periprocedural anticoagulation strategies in patients
on dabigatran undergoing AF ablation.
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